Page 55 - நாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) Acumen Pharmaceuticals, Inc. (“Acumen” or “Acumen Pharmaceuticals”) (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what Acumen believes to be a key underlying cause of Alzheimer’s disease, today announced the pricing of its upsized initial public offering of 9,999,999 shares of common stock at a public offering price of $16.00 per share. The gross proceeds to Acumen, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $160 million. All of the shares of common stock are being offered by Acumen. In addition, Acumen has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

United statesSan franciscoNicolaus company incorporatedCredit suisseAcumen or pharmaceuticals nasdaqCredit suisse securities united statesAcumen pharmaceuticalsInvestment bankAcumen pharmaceuticals incExchange commissionProspectus departmentNasdaq global select marketBofa securitiesCollege streetSuisse securitiesStephens drive